Celularity Inc. Increase Decrease In Operating Lease Liability
Celularity Inc. (CELU) reported Increase Decrease In Operating Lease Liability of $350.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-04-30
- Celularity Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was $92.00K, a 5.15% decline year-over-year.
- Celularity Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was $89.00K, a 6.32% decline year-over-year.
- Celularity Inc. increase decrease in operating lease liability for the quarter ending 2025-06-30 was $86.00K, a 5.49% decline year-over-year.
- Celularity Inc. increase decrease in operating lease liability for the quarter ending 2025-03-31 was $83.00K, a 5.68% decline year-over-year.
- Celularity Inc. increase decrease in operating lease liability for fiscal 2025 was $350.00K, a 5.66% decline from fiscal 2024.
- Celularity Inc. increase decrease in operating lease liability for fiscal 2024 was $371.00K, a 34.91% increase from fiscal 2023.
- Celularity Inc. increase decrease in operating lease liability for fiscal 2023 was $275.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $181.00K derived: sum of 2 quarters · filed 2026-04-30 | $267.00K derived: sum of 3 quarters · filed 2026-04-30 | $350.00K 10-K · filed 2026-04-30 |
| 2025-09-30 | $89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $175.00K derived: sum of 2 quarters · filed 2025-11-14 | $258.00K 10-Q · filed 2025-11-14 | $355.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-06-30 | $86.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $169.00K 10-Q · filed 2025-08-29 | $266.00K derived: sum of 3 quarters · filed 2026-04-30 | $361.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2025-03-31 | $83.00K 10-Q · filed 2025-08-29 | $180.00K derived: sum of 2 quarters · filed 2026-04-30 | $275.00K derived: sum of 3 quarters · filed 2026-04-30 | $366.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $192.00K derived: sum of 2 quarters · filed 2026-04-30 | $283.00K derived: sum of 3 quarters · filed 2026-04-30 | $371.00K 10-K · filed 2026-04-30 |
| 2024-09-30 | $95.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $186.00K derived: sum of 2 quarters · filed 2025-11-14 | $274.00K 10-Q · filed 2025-11-14 | $377.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $91.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $179.00K 10-Q · filed 2025-08-29 | $282.00K derived: sum of 3 quarters · filed 2025-08-29 | $337.00K derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | $88.00K 10-Q · filed 2025-08-29 | $191.00K derived: sum of 2 quarters · filed 2025-08-29 | $246.00K derived: sum of 3 quarters · filed 2025-08-29 | $299.00K derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | $103.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $158.00K derived: sum of 2 quarters · filed 2025-05-08 | $211.00K derived: sum of 3 quarters · filed 2025-05-08 | $275.00K 10-K · filed 2025-05-08 |
| 2023-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | $108.00K derived: sum of 2 quarters · filed 2024-12-06 | $172.00K 10-Q · filed 2024-12-06 | |
| 2023-06-30 | $53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $117.00K 10-Q · filed 2024-11-07 | ||
| 2023-03-31 | $64.00K 10-Q · filed 2024-10-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |